Immix Biopharma, INC

Immix Biopharma, Inc. announced the termination of Richard Graydon as an officer of the company, effective July 17, 2026.

Immix Biopharma stockholders re-elected all director nominees and ratified the appointment of Crowe LLP as independent auditors.

Immix Biopharma has priced an underwritten public offering of 16,778,524 shares of common stock at $8.94 per share to raise $150 million in gross proceeds.

Immix Biopharma announced a 95% complete response rate in its Phase 2 NEXICART-2 trial for AL Amyloidosis, with all MRD-negative patients achieving CR.

Immix Biopharma announced the completion of enrollment for its NEXICART-2 clinical trial for NXC-201, with topline results anticipated in Q3 2026, paving the way for a Biologics License Application submission and commercial launch.

Immix Biopharma, Inc. amended its At The Market offering agreement to allow for the sale of up to $100 million in common stock.

Immix Biopharma's Q2 2026 10-Q filing details substantial capital raises, positive interim clinical trial data for NXC-201, and ongoing operational losses.

Immix Biopharma reports Q1 2026 financial results, highlighting clinical progress for NXC-201 and a strong cash position of $90.6 million.

Immix Biopharma reported increased Q3 losses and a going concern warning, while securing new capital and advancing its NXC-201 CAR-T therapy with positive clinical data and RMAT designation.

Immix Biopharma reported increased net losses in Q2 2025 due to higher R&D expenses for its promising NXC-201 CAR-T therapy, which continues to show strong clinical efficacy and has received key regulatory designations.

Immix Biopharma files an amendment to its original Q1 2025 report to include certifications from the CEO and CFO as required by Sarbanes-Oxley Act.

Immix Biopharma reports a net loss of $4.54 million for Q1 2025, with ongoing clinical trials and CIRM grant reimbursements impacting financial results.

Immix Biopharma, Inc. filed an amendment to its 2025 Annual Report on Form 10-K, primarily to correct the auditor report date, while revealing significant capital raises and increased liquidity despite growing net losses.

Immix Biopharma reports positive interim Phase 2 data for its lead CAR-T candidate NXC-201 in AL Amyloidosis, alongside significant capital raises and key regulatory designations.

Immix Biopharma files an amendment to its 2024 annual report to include required XBRL tagging and reaffirms certifications from its principal executive and financial officers.

Immix Biopharma's 2024 10-K filing details financial results, NXC-201 clinical trial progress, and recent RMAT designation for relapsed/refractory AL amyloidosis.

Immix Biopharma's 2023 annual report details ongoing clinical trials, financial losses, and strategic developments in their pursuit of novel cancer and autoimmune therapies.

Director Helen C. Adams acquired 6,250 restricted stock units and 12,500 stock options as part of an equity incentive plan.

Director Carey Ng was granted 6,250 restricted stock units and 12,500 stock options by Immix Biopharma, Inc.

Director Magda Marquet was granted 6,250 restricted stock units and 12,500 stock options by Immix Biopharma, Inc.

Immix Biopharma CFO and President Gabriel S. Morris was granted 500,000 stock options vesting over 48 months.

Director Nancy T. Chang was granted 6,250 restricted stock units and 12,500 stock options as part of the company's 2021 Equity Incentive Plan.

Immix Biopharma CEO and Chairman Ilya M. Rachman was granted 500,000 stock options vesting over 48 months.

Immix Biopharma, Inc. has issued a proxy statement for its 2026 Annual Meeting of Stockholders, detailing proposals for director elections and auditor ratification.

Immix Biopharma files a supplement to its proxy statement to include Inline XBRL tagging for insider trading and equity grant policies, and to add a description of its clawback policy.

Immix Biopharma announces its annual stockholders meeting to be held on June 20, 2025, featuring the election of eight directors and ratification of its accounting firm.

Immix Biopharma announces its 2025 annual meeting of stockholders to elect directors and ratify the appointment of its independent auditor.

Immix Biopharma, Inc. has filed a definitive proxy statement with the SEC.

Immix Biopharma announces its annual stockholders meeting to be held on June 11, 2024, to elect directors, ratify the appointment of its accounting firm, and approve amendments to its equity incentive plan.

Eventide Asset Management, LLC, along with Finny Kuruvilla and Robin C. John, has reported beneficial ownership of 5.6% of Immix Biopharma, Inc.'s common stock as of June 30, 2026.

Janus Henderson Group Ltd. has disclosed beneficial ownership of 9,783,192 shares, representing 14.0% of Immix Biopharma, Inc.'s common stock, through various asset managers.

Janus Henderson Group plc has reported a 13% beneficial ownership stake in Immix Biopharma, Inc. through its various investment management subsidiaries.

Janus Henderson Group plc has reported beneficial ownership of 4,802,002 shares, representing 9.1% of Immix Biopharma, Inc.'s common stock, as of March 31, 2026.

Millennium Management LLC, Millennium Group Management LLC, and Israel A. Englander have jointly filed a Schedule 13G, disclosing beneficial ownership of 3.3% of Immix Biopharma, Inc. common stock as of March 31, 2026.

Millennium Management LLC and affiliated entities have reported a 5.3% beneficial ownership stake in Immix Biopharma, Inc. common stock.